After lawmakers rejected a Republican-led amend to the measure to restore its original provisions, which would have allowed for broad legalization of facilitated use, a psilocybin bill passed the Washington State House Committee.
Rep. Travis Couture (R), who introduced this amendment, stated that “This is something which is–to my–low risk, something we can try now.” “I don’t believe that, with the pace we are moving, we’re moving fast enough,” said Travis Couture (R).
Sens. originally introduced SB5263. Jesse Salomon and Liz Lovelett (D), introduced a bill in January to allow adults aged 21 or older to legally use psilocybin with the assistance of state-licensed facilitators. According to the original bill, nationally recognized medical institutions recognize psilocybin as a treatment for a wide range of conditions.
The bill was then rescinded by centrist Democrats in the Senate committees. They created a task group and advisory group to examine the issue, make recommendations, and remove legalization provisions. It passed as a research-only bill in the Senate last month.
On Tuesday , the House Appropriations Committee approved a revised version of the bill. It is similar to the Senate-passed bill with one exception: A new clinical trial program administered by the University of Washington (UW) that would provide legal psilocybin accessibility to veterans and first responders. The details of the program, which will need to start by 2025 are still unclear.
Marijuana Moment tracks more than 1000 cannabis, psychedelics, and drug policy bills in the state legislatures and Congress this yea. Patreon supporters who pledge at least $25 per month get access to our interactive maps and charts, as well as a hearing calendar, so they don’t miss any developments.
Get access to our marijuana bill tracker by becoming a Patreon supporter.
—
Couture, a veteran of the military, stated that he appreciates the bill as it stands, but believes there is a need to offer safer alternatives to unregulated, illegal drugs being used by many veterans. He said that, especially as we end a decade-long war, there are many veterans returning, and mental illness, and PTSD, is a serious problem. We have higher suicide rates among veterans who are homeless than we do veterans who commit suicide.
Couture stated that the original plan to legalize marijuana services had “put some sideboards around” it. “We have someone to facilitate it and the experts at the Department of Health who will do rulemaking around it. This is why I encourage everyone to really think about it.”
Rep. Nicole Macri (D), introduced an amendment to create UW pilot program last Wednesday in a separate commission and urged that Couture be rejected. She asked her colleagues to “instead, move in a more systematic and thoughtful manner.”
Couture was told by Couture that she didn’t believe they were alone in believing Washington should act faster to legalize psilocybin. But I believe it’s important to take thoughtful, measured steps towards a fully regulated marketplace. There is still much to do.
The bill’s current form is not popular with outside advocates of psilocybin legislation. They acknowledge that it is a symbolic step towards ending the criminal drug war. They are concerned that the bill’s promise to only research legalization -which has already taken place at the state level in Washington and local level in Washington – could set back more substantial reforms by many years.
Kody Zalewski is co-director of the Psychedelic Medical Alliance Washington (PMAW). He said that even Macri’s UW clinical trial might slow down access to psilocybin.
Marijuana Moment received an email from Zalewski saying that while they are pleased with the treatment available, “the length of these trials could be a setback.” “Lawmakers may not revisit this issue until the final trial results have been published, which could delay implementation for many years.”
Marijuana Moment asked Macri for comment Tuesday, but he did not respond immediately.
PMAW had previously encouraged legislators to look into an alternative pilot program, which would have given participants grant money to be eligible for legal psilocybin service in Oregon.
Zalewski stated that this would be faster, more cost-effective, and offer greater access. The bill’s original structure was based on Oregon’s Initiative 109. Therefore, the alternative program could have been more representative than the UW-administered clinical trial.
While some legislators on the right and left would like to see the state take psilocybin reform more quickly, they have faced constant opposition from both morally outraged Republicans and centrist Democrats. Rep. Mary Dye (R), representing the latter group at Tuesday’s hearing, warned that the bill was “code to do more than that for therapeutic purposes.”
She stated that she was concerned about the use of psychedelics in rave concerts. “These concerts are reminiscent the ’60s & ’70s, as well as that counterculture subculture accepting those psychedelic experiences.”
Dye stated that if the therapeutic is therapeutic, Dye believes it should go through FDA to become a pharmaceutical. The therapeutic would be administered in a clinical setting by a doctor.
According to the current bill, the UW clinical pilot program must offer psilocybin treatment services through approved pathways by the federal food drug administration [FDA]”.
Anthony Back, a Seattle physician and professor of medicine at UW, spoke to lawmakers earlier this year. He is currently leading a clinical study of psilocybin assisted therapy for nurses and doctors with depression related to their work on the COVID pandemic.
Back testified before a Senate committee, “Obviously it would have been wonderful if we could delay until the incredibly definitive results from everything.” “But I can tell you that I have witnessed remarkable responses from clinicians suffering in a way which completely prevented them from doing the work that they love.
He also warned legislators that depriving adults of legal psilocybin poses its own set safety and health risks.
He said that he had heard of “desperate clinicians” who sought underground care. “Including a nurse who was sexually assaulted and unlicensed by an underground provider.”
Washington’s legislature is currently considering a number of drug policy bills. This includes legislation that would allow state-licensed businesses to engage in interstate cannabis commerce if federal officials permit it.
Another bill, though slightly different, has passed both houses of legislature. It would prohibit employers discriminating against applicants for jobs who have used or tested positive for marijuana. Workers who are already employed would not be protected.
The proposal to legalize home cultivation by adult for personal purposes was also considered again by lawmakers, but it was not adopted. The act is currently a felony in the State.
New Biden Proclamation Highlights Marijuana Criminalization’s Role in Blocking Employment And Education
The post Washington Psilocybin Research Bill Heads to House Floor After Panel Rejects GOP push To Restore Legal Use originally appeared on Marijuana Moment.
